Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

If approved, apitegromab could soon face competition from other myostatin inhibitors in late-stage development, including Biohaven’s taldefgrobep alfa and Roche’s GYM329 (also known as RO7204239).

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Research suggests that the peptide may function as a competitive antagonist to myostatin, thereby impacting muscle cell proliferation. Research indicates that Follistatin-344 may interact with activin ...

Nicotinic acetylcholine (ACh) receptors and other Cys-loop receptors challenge our ability to understand how proteins carry out simple sets of functions — in this case, specific binding ...

What new targets will iBio announce during the call? iBio will announce a third target in the AstralBio Collaboration, alongside Myostatin and Activin E. Where can I find the webcast of the call?

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss ...

Angiotensin II (AT-II)-Receptor Antagonists are Reviewed. Research focused on blocking the renin- angiotensin system (RAS) led to the discovery of angiotensin-converting-enzyme (ACE) inhibitors ...